Enanta Pharmaceuticals Inc.
- ENTA · Nasdaq
- Pharmaceutical Preparations
- Watertown, MA
- 120 employees
- CIK 0001177648
Updated from SEC filings through
Top things to know
Executives
- Jay R. Luly President and CEO 4, 2026-02-13
- Harry R. Trout III Vice President, Finance (Principal Financial Office r) 10-Q, 2026-08-12
-
Scott T. Rottinghaus Chief Medical Officer 4, 2026-08-10 -
Brendan Luu Chief Business Officer 4, 2026-02-13 - Matthew Paul Kowalsky Chief Legal Officer 4, 2026-02-13
- Tara Lynn Kieffer Chief Product Strategy Officer 4, 2026-02-13
Enanta Pharmaceuticals Inc is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Watertown, MA. It trades as ENTA on Nasdaq. Revenue was $65.3M in the fiscal year ending September 30, 2025, -3.4% from the year before. It reported about 120 employees. Jay R. Luly is President and CEO.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $65.3M 10-K, 2025-11-19 | $67.6M 10-K, 2025-11-19 | $79.2M 10-K, 2025-11-19 | $86.2M 10-K, 2024-11-27 | $97.1M 10-K, 2023-11-22 |
| Operating income | -$85.3M 10-K, 2025-11-19 | -$122M 10-K, 2025-11-19 | -$137M 10-K, 2025-11-19 | -$124M 10-K, 2024-11-27 | -$110M 10-K, 2023-11-22 |
| SG&A | $43.9M 10-K, 2025-11-19 | $57.9M 10-K, 2025-11-19 | $52.9M 10-K, 2025-11-19 | $45.5M 10-K, 2024-11-27 | $32.5M 10-K, 2023-11-22 |
| Net income | -$81.9M 10-Q, 2026-08-12 | -$116M 10-K, 2025-11-19 | -$134M 10-K, 2025-11-19 | -$122M 10-K, 2024-11-27 | -$79.0M 10-K, 2023-11-22 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Jay R. Luly | President and CEO | 4, 2026-02-13 |
| Harry R. Trout III Principal Financial Officer and VP, Finance at Enanta Pharmaceuticals | Vice President, Finance (Principal Financial Office r) | 10-Q, 2026-08-12 |
| Scott T. Rottinghaus Chief Medical Officer at Enanta Pharmaceuticals | Chief Medical Officer | 4, 2026-08-10 |
| Brendan Luu Chief Business Officer at Enanta Pharmaceuticals | Chief Business Officer | 4, 2026-02-13 |
| Matthew Paul Kowalsky | Chief Legal Officer | 4, 2026-02-13 |
| Tara Lynn Kieffer | Chief Product Strategy Officer | 4, 2026-02-13 |
| Yat Sun Or | Chief Scientific Officer | 4, 2026-02-13 |
| Tara L. Kieffer, Ph.D. | Named in proxy bio: Chief Product Strategy Officer | DEF 14A, 2026-01-26 |
| Terry C. Vance | Board member (per proxy) bio: member of our Board of Directors | DEF 14A, 2026-01-26 |
| Kathleen S. Capps | Executive Director of Accounting, Controller | 10-K, 2025-11-19 |
| Bruce L.A. Carter, Ph.D. | Director | 10-K, 2025-11-19 |
| Kristine Peterson | Director | 10-K, 2025-11-19 |
| Lesley Russell, MB. Ch.B., MRCP | Director | 10-K, 2025-11-19 |
| Mark G. Foletta | Director | 10-K, 2025-11-19 |
| Terry Vance | Director | 10-K, 2025-11-19 |
| Yujiro S. Hata | Director | 10-K, 2025-11-19 |
What Enanta Pharmaceuticals Inc does
We discovered glecaprevir, the second of two antiviral protease inhibitors developed through our collaboration with AbbVie for the treatment of acute or chronic infection with hepatitis C virus, or HCV.S.)S.) (glecaprevir/pibrentasvir) since 2017 for the treatment of chronic HCV. MAVYRET ® was also approved as the first and only treatment for acute HCV infection in June 2025.
Item 1. Business, 10-K for the year ending September 30, 2025
Shares and governance
| Shares outstanding | 29.1 million (as of August 7, 2026) | 10-Q, August 12, 2026 |
|---|---|---|
| Public float | $111M (as of March 31, 2025) | 10-K, November 19, 2025 |
| Latest proxy statement | Meeting March 11, 2026 (filed January 26, 2026) | DEF 14A, January 26, 2026 |
| Auditor | PricewaterhouseCoopers LLP (Boston, Massachusetts) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| December 5, 2025 | Kathleen S. Capps See Remarks | Sale | 323 | $5K | Form 4, December 5, 2025 |
| December 5, 2025 | Harry R. Trout III See Remarks | Sale | 542 | $8K | Form 4, December 5, 2025 |
| December 5, 2025 | Scott T. Rottinghaus Chief Medical Officer | Sale | 798 | $11K | Form 4, December 5, 2025 |
| December 5, 2025 | Brendan Luu Chief Business Officer | Sale | 1,394 | $20K | Form 4, December 5, 2025 |
| December 5, 2025 | Tara Lynn Kieffer Chief Product Strategy Officer | Sale | 2,106 | $30K | Form 4, December 5, 2025 |
| December 5, 2025 | Yat Sun Or Chief Scientific Officer | Sale | 2,390 | $34K | Form 4, December 5, 2025 |
| December 5, 2025 | Jay R. Luly President and CEO | Sale | 4,743 | $67K | Form 4, December 5, 2025 |
| December 2, 2025 | Kathleen S. Capps See Remarks | Sale | 207 | $3K | Form 4, December 3, 2025 |
Recent 8-K events
- 8-K filed 2026-10-29
- Item 8.01 Other events
- 8-K filed 2026-10-28
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-08-10
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-07-02
- Item 1.01 Entry into a material definitive agreement
- 8-K filed 2026-06-23
- Item 8.01 Other events
- 8-K filed 2026-06-18
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-05-11
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-03-26
- Item 8.01 Other events
- 8-K filed 2026-03-12
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-02-09
- Item 2.02 Results of operations and financial condition (earnings release)
Frequently asked questions about Enanta Pharmaceuticals Inc
- What does Enanta Pharmaceuticals Inc do?
- In its own words, from Item 1 of its 10-K: "We discovered glecaprevir, the second of two antiviral protease inhibitors developed through our collaboration with AbbVie for the treatment of acute or chronic infection with hepatitis C virus, or HCV.S.)S.) (glecaprevir/pibrentasvir) since 2017 for the treatment of chronic HCV. MAVYRET ® was also approved as the first and only treatment for acute HCV infection in June 2025."
- What is Enanta Pharmaceuticals Inc's revenue?
- $65.3M for the fiscal year ending September 30, 2025, from its 10-K filed November 19, 2025.
- Is Enanta Pharmaceuticals Inc profitable?
- Enanta Pharmaceuticals Inc reported net income of -$81.9M for the fiscal year ending September 30, 2025.
- How many employees does Enanta Pharmaceuticals Inc have?
- About 120 as of September 30, 2025, as stated in its annual report.
- Who is the CEO of Enanta Pharmaceuticals Inc?
- Jay R. Luly, President and CEO, as named in a 4 filed February 13, 2026.
- Where is Enanta Pharmaceuticals Inc headquartered?
- Watertown, MA.
- What is Enanta Pharmaceuticals Inc's stock ticker?
- ENTA on Nasdaq.
- What industry is Enanta Pharmaceuticals Inc in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Enanta Pharmaceuticals Inc's website?
- enanta.com.
- When does Enanta Pharmaceuticals Inc report earnings next?
- November 16, 2026. Source: pg_future_events.
- Is Enanta Pharmaceuticals Inc a public company?
- Yes. Enanta Pharmaceuticals Inc files with the SEC under CIK 0001177648 and trades as ENTA.
- Who audits Enanta Pharmaceuticals Inc?
- PricewaterhouseCoopers LLP, Boston, Massachusetts, as named in its latest annual report (10-K).
- How many shares of Enanta Pharmaceuticals Inc are outstanding?
- 29.1 million shares as of August 7, 2026, from its 10-Q filed August 12, 2026.
- What is Enanta Pharmaceuticals Inc's public float?
- $111M as of March 31, 2025, as reported on the cover of its 10-K filed November 19, 2025.
- When is Enanta Pharmaceuticals Inc's annual shareholder meeting?
- March 11, 2026, per its proxy statement (DEF 14A) filed January 26, 2026.
- Have Enanta Pharmaceuticals Inc insiders traded stock recently?
- Since December 2, 2025, officers and directors reported 9 open-market sales worth about $183K and 0 purchases on Forms 4 and 5. The most recent: Kathleen S. Capps (See Remarks) sold 323 shares on December 5, 2025.